LTI-03

DRUG3 trials

Sponsors

Rein Therapeutics Inc., Rein Therapeutics

Conditions

Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)

Phase 1

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

CompletedNCT05954988

Rein TherapeuticsIdiopathic Pulmonary Fibrosis

Start: 2023-07-06End: 2024-09-25Updated: 2025-07-31

Phase 2

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

RecruitingNCT06968845

Rein TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)

Start: 2026-02-02End: 2027-12-31Target: 120Updated: 2026-03-31

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW)

Not yet recruitingCTIS2025-520715-13-00

Rein Therapeutics Inc.Idiopathic Pulmonary Fibrosis

Target: 28Updated: 2025-10-06

Related Papers

Pre-clinical Proof-of-Concept of Anti-fibrotic Activity of Caveolin-1 Scaffolding Domain Peptide LTI-03 in Ex Vivo Precision Cut Lung Slices From Patients With Idiopathic Pulmonary Fibrosis

American Journal of Respiratory and Critical Care Medicine2025-05-01